Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting
May 23 2019 - 7:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that clinical data and important
findings from studies of lead candidate odevixibat (A4250) in
biliary atresia, Alagille syndrome and progressive familial
intrahepatic cholestasis have been selected for presentation at the
52nd European Society for Paediatric Gastroenterology, Hepatology
and Nutrition (ESPGHAN) Annual Meeting, being held June 5-8, 2019,
at the Scottish Event Campus in Glasgow, Scotland.
Details of the presentations are as follows:
Title: Effects of the ileal bile acid
transport inhibitor A4250 on serum bile acids, pruritus and sleep
in patients with Alagille syndrome: phase 2 study results
Presentation Number: H-O-006
Session: Plenary Session: Hepatology
Date / Time: Friday, June 7, 8:40-8:50 a.m. BST /
3:40-3:50 a.m. EST
Presenter: Dr. Ulrich Baumann, Professor of
Pediatric Gastroenterology and Hepatology, Hannover Medical
School; Hannover, Germany
Title: Development of patient- and
observer-reported outcome measures for paediatric cholestatic liver
diseases Poster
Number: H-P-138Session: Poster
ExhibitionDate / Time: Friday, June
7, 2-2:45 p.m. BST / 9-9:45 a.m. EST
Presenter: Dr. Richard J. Thompson, Professor
of Molecular Hepatology, Institute of Liver Studies, King’s College
Hospital; London, United Kingdom
Title: Effects of the ileal bile acid
transport inhibitor A4250 on pruritus and serum bile acids in
patients with biliary atresia: phase 2 study results Poster
Number: H-P-029Session: Poster
Exhibition Date / Time: Friday, June
7, 2-2:45 p.m. BST / 9-9:45 a.m. EST
Presenter: Dr. Ulrich Baumann, Professor of
Pediatric Gastroenterology and Hepatology, Hannover Medical
School; Hannover, Germany
Title: Impact of an ileal bile acid
transporter inhibitor versus partial external biliary diverson in
progressive familial intrahepatic cholestasis – a case providing
direct comparison of medical and surgical therapiesPoster
Number: H-P-130Session: Poster
Exhibition Date / Time: Friday, June
7, 2-2:45 p.m. BST / 9-9:45 a.m. EST
Presenter: Christoph Slavetinsky, MD, Ph.D.,
Pediatric Gastroenterology and Hepatology, University Children's
Hospital Tubingen; Tubingen, Germany
The ESPGHAN Annual Meeting brings together more than 4,600
participants from 100 countries to exchange new ideas and discuss
the latest research in gastroenterology, hepatology and nutrition.
For more information about the conference, visit
https://www.espghancongress.org.
About Albireo Albireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, odevixibat (A4250), is being developed to treat
rare pediatric cholestatic liver diseases and is in Phase 3
development in its initial target indication, progressive familial
intrahepatic cholestasis (PFIC). Albireo’s clinical pipeline also
includes two Phase 2 product candidates. Albireo’s elobixibat,
approved in Japan for the treatment of chronic
constipation, is the first ileal bile acid transporter (IBAT)
inhibitor approved anywhere in the world.
Albireo was spun out from AstraZeneca in
2008. Albireo Pharma is located
in Boston, Massachusetts, and its key operating
subsidiary is located in Gothenburg, Sweden. For more
information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC, 212-915-2568Media Contact: Heather
Anderson, 6 Degrees, 980-938-0260,
handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024